Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (602)	3/4/1999 8:35:00 PM
From: Omer Shvili	Read Replies (2) of 1386

John, Your interpretation about "gearing up for PIII" is quite correct. PARS has been doing a lot of work for the upcoming PIII HU211 trials. Anything PARS can do without a partner, is being done. Meaning, all of the preliminary work (talks with FDA, design of study etc.). This is being done in order to shorten the waiting period between signing a partner and the actual start of PIII. Another important part of the Q4 press release, is the fact that there were still inventory draw-downs at distributors during the quarter (that's the question I kept asking the company, the minute they announced sales levels). I also understand there were still some samples during Q4 (much less than in Q3). All these should decline dramatically in Q1, so revenues in Q1 will be more revealing of the true story, and of how BOL is advancing. I believe we'll see very strong growth in Q1 and the following quarters. Omer

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next